Are EORTC risk tables usefull in evaluating the results of patients with non-muscle invasive bladder cancer submitted to WL TURBT? RUA’s experience
The aim of the study was to assess the EORTC risk tables usefulness in daily urological practice.
Materials and methods.
444 pts treated for non-muscle invasive bladder cancer with WL bipolar TURBT were analyzed. After performed WL TURBT 6 risk factors were assessed and basing on mentioned factors and using the EORTC scoring system the total score for recurrence and progression for each patient was calculated separately.
According to the total score, patients were divided into 4 recurrence
risk groups. Patients with total recurrence score 0 were classified to group I, 1-4 points to group II, 5-9 to group III, and 10-17 to group IV risk of recurrence. During follow-up, in according to EAU guidelines for non muscle invasive bladder cancer, a WLTURBT on suspected lesions or scars was carried
23,8’%pts developed recurrent bladder tumor in 12 months of follow-up. The risk of bladder tumor recurrence was statistically higher in intermediate-risk group. The recurrence rate was 0%, 28,6%, 44.7%, and 17,4% in I, II, III and IV recurrence risk group, respectively. About the staging and grading we observed a recurrence rate in PUNMPL group of 3,48%, in pTaLG of 6,55%, in pTaHG of 9,42%, in pT1LG of 1,02 %, in pT1HG of 6,96% and in pCISHG dell’1,84%.
The risk of bladder tumor progression was statistically higher in intermediate-risk group. we observed a progression in the 1,9% of PUNMPL, in the 53,8% of the pTaLG, in the 36,5% of the pTaHG, in the 1,92 % of the pT1LG and in the 7,6% of the pCISHG.
Using EORTC nomograms it is possible to separately estimate
the risk of recurrence and progression for patients treated with TUR for primary or recurrent non-muscle invasive bladder cancer.